Evotec

Sanofi and Evotec to collaborate on diabetes therapies

Monday, August 10, 2015

Evotec, a drug discovery alliance and development partnership company based in Germany, and Sanofi have announced a strategic diabetes collaboration to develop a beta cell replacement therapy based on functional human beta cells derived from human stem cells. In addition, Sanofi and Evotec will use human beta cells for high-throughput drug screening to identify beta-cell-active small molecules or biologics.

[Read More]

Evotec, Roche provide initial update from phase IIb trial in Alzheimer’s disease

Wednesday, July 8, 2015

Evotec was updated by its partner Roche on the initial results of the phase IIb trial with Sembragiline (RG1577, EVT302), a MAO-B inhibitor for the treatment of Alzheimer’s disease (AD). In this study, Sembragiline failed to demonstrate benefit on the primary endpoint (Alzheimer’s Disease Assessment Scale—Cognitive Behaviour Subscale, ADAS-cog-11) after 52 weeks of treatment.

[Read More]

Sanofi, Evotec collaborate to reinforce biomedical research in Toulouse

Wednesday, March 25, 2015

Sanofi has signed a strategic collaboration agreement with Evotec, a drug discovery alliance and development partnership company, for scientific activities at the Sanofi R&D site in Toulouse (Haute-Garonne), France. This strategic collaboration aims to sustain a high level of scientific and technological activities, maintain jobs and attract new talent and projects to the site.

[Read More]

Evotec, Padlock Therapeutics extend collaboration

Monday, January 12, 2015

Evotec, a Germany-based drug discovery alliance and development partnership company, and Padlock Therapeutics, a private, Cambridge, Mass.-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases, have successfully completed an initial goal in a program focused on developing inhibitors of protein-arginine deiminases (PADs) and have further extended the collaboration that was first signed in January 2014.

[Read More]

Evotec, Sanofi to collaborate

Wednesday, December 3, 2014

Evotec has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years. The collaboration will comprise three major strategic initiatives all focused on improving innovation effectiveness in the drug discovery and preclinical development space.

[Read More]

Evotec, CHDI Foundation extend ongoing Huntington’s disease collaboration

Friday, September 12, 2014

The CHDI Foundation, a U.S. privately-funded nonprofit biomedical research organization, has extended and restated its collaboration with Evotec, a drug discovery solutions company based in Germany, through 2017. The collaboration, which aims to find new treatments for Huntington’s disease, an inherited neurodegenerative disorder, means CHDI will fund up to 52 full-time scientists at Evotec over the next three years.

[Read More]